Haleon (LON:HLN) Shares Down 1.9% – Should You Sell?

Haleon plc (LON:HLN)’s share price was down 1.9% during mid-day trading on Monday . The company traded as low as GBX 382.60 ($4.94) and last traded at GBX 385.50 ($4.98). Approximately 14,722,720 shares changed hands during mid-day trading, a decline of 48% from the average daily volume of 28,321,533 shares. The stock had previously closed at GBX 393.15 ($5.08).

Wall Street Analyst Weigh In

Separately, Berenberg Bank increased their price objective on shares of Haleon from GBX 456 ($5.89) to GBX 457 ($5.91) and gave the company a “buy” rating in a report on Friday, February 28th.

Haleon Price Performance

The company has a debt-to-equity ratio of 53.36, a current ratio of 0.84 and a quick ratio of 0.93. The stock has a market capitalization of £34.79 billion, a price-to-earnings ratio of 32.42, a price-to-earnings-growth ratio of 1.49 and a beta of 0.19. The stock has a 50 day moving average price of GBX 385.76 and a 200-day moving average price of GBX 381.76.

Haleon (LON:HLN) last issued its earnings results on Friday, February 28th. The company reported GBX 15.80 ($0.20) earnings per share for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. On average, analysts forecast that Haleon plc will post 19.5033282 earnings per share for the current year.

Haleon Increases Dividend

The company also recently declared a dividend, which will be paid on Thursday, June 5th. Stockholders of record on Thursday, April 24th will be given a dividend of GBX 4.60 ($0.06) per share. This is a boost from Haleon’s previous dividend of $2.00. The ex-dividend date of this dividend is Thursday, April 24th. This represents a dividend yield of 1.18%. Haleon’s payout ratio is presently 50.46%.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.